| Drug Name |
Dolutegravir sodium |
| Drug ID |
BADD_D00704 |
| Description |
Dolutegravir is a HIV-1 intergrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI).[A7514] The effect of this drug has no homology in human host cells which gives it an excellent tolerability and minimal toxicity.[A31342] Dolutegravir was developed by ViiV Healthcare and FDA approved on August 12, 2013.[L1035] On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca.[L1031] |
| Indications and Usage |
Dolutegravir is indicated in combination with other antiretroviral agents for the treatment of patients with HIV-1 infection that comply with the characteristics of being adults or children aged 12 years and older and present at least a weight of 40 kg.[A7520] The FDA combination therapy approval of dolutegravir and rilpivirine is indicated for adults with HIV-1 infections whose virus is currently suppressed (< 50 copies/ml) on a stable regimen for at least six months, without history of treatment failure and no known substitutions associated to resistance to any of the two components of the therapy.[L1031] |
| Marketing Status |
approved |
| ATC Code |
J05AJ03 |
| DrugBank ID |
DB08930
|
| KEGG ID |
D10113
|
| MeSH ID |
C562325
|
| PubChem ID |
46216142
|
| TTD Drug ID |
D00YZD
|
| NDC Product Code |
42931-242; 65862-962; 53808-1130; 52482-016; 68554-0093; 49702-255; 53044-001; 63379-067; 63379-077; 69766-023; 63379-062; 63379-063; 82245-0202; 49702-226; 49702-227; 49702-228; 69037-0044 |
| UNII |
1Q1V9V5WYQ
|
| Synonyms |
dolutegravir | (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid- 2,4 difluorobenzylamide | (4R,12aS)-N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide | dolutegravir sodium | S-GSK1349572 | GSK-1349572 | dolutegravir sodium monohydrate | Tivicay | GSK 1349572A | GSK1349572A |
